HuGE Literature Finder
Records 1-30
|
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Breast cancer research : BCR 2020 Oct 22 (1): 107. Fumagalli Caterina, Ranghiero Alberto, Gandini Sara, Corso Federica, Taormina Sergio, De Camilli Elisa, Rappa Alessandra, Vacirca Davide, Viale Giuseppe, Guerini-Rocco Elena, Barberis Massi |
|
Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
Breast cancer research : BCR 2020 Aug 22 (1): 91. van Geelen Courtney T, Savas Peter, Teo Zhi Ling, Luen Stephen J, Weng Chen-Fang, Ko Yi-An, Kuykhoven Keilly S, Caramia Franco, Salgado Roberto, Francis Prudence A, Dawson Sarah-Jane, Fox Stephen B, Fellowes Andrew, Loi Shere |
|
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Breast cancer research and treatment 2020 Aug . Skriver Signe Korsgaard, Jensen Maj-Britt, Eriksen Jens-Ole, Ahlborn Lise Barlebo, Knoop Ann Soegaard, Rossing Maria, Ejlertsen Bent, Laenkholm Anne-Vibe |
|
PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Aug . Guarneri Valentina, Dieci Maria Vittoria, Bisagni Giancarlo, Brandes Alba A, Frassoldati Antonio, Cavanna Luigi, Musolino Antonino, Giotta Francesco, Rimanti Anita, Garrone Ornella, Bertone Elena, Cagossi Katia, Nanni Oriana, Piacentini Federico, Orvieto Enrico, Griguolo Gaia, Curtarello Matteo, Urso Loredana, Paré Laia, Chic Nuria, D'Amico Roberto, Prat Aleix, Conte PierFran |
|
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Breast cancer research and treatment 2020 Jul . Li Kai, Liao Ning, Chen Bo, Zhang Guochun, Wang Yulei, Guo Liping, Wei Guangnan, Jia Minghan, Wen Lingzhu, Ren Chongyang, Cao Li, Mok Hsiaopei, Li Cheukfai, Lin Jiali, Chen Xiaoqing, Zhang Zhou, Hou Ting, Li Min, Liu Jing, Balch Charles M, Liao Ni |
|
Landscape of circulating tumour DNA in metastatic breast cancer.
EBioMedicine 2020 Jul 58 102914. Davis Andrew A, Jacob Saya, Gerratana Lorenzo, Shah Ami N, Wehbe Firas, Katam Neelima, Zhang Qiang, Flaum Lisa, Siziopikou Kalliopi P, Platanias Leonidas C, Gradishar William J, Behdad Amir, Cristofanilli Massi |
|
Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Jun . Sun Xiangjie, Zuo Ke, Yao Qianlan, Zhou Shuling, Shui Ruohong, Xu Xiaoli, Bi Rui, Yu Baohua, Cheng Yufan, Tu Xiaoyu, Lu Hongfen, Yang Went |
|
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Breast cancer research : BCR 2020 May 22 (1): 45. Martínez-Sáez Olga, Chic Nuria, Pascual Tomás, Adamo Barbara, Vidal Maria, González-Farré Blanca, Sanfeliu Esther, Schettini Francesco, Conte Benedetta, Brasó-Maristany Fara, Rodríguez Adela, Martínez Débora, Galván Patricia, Rodríguez Ana Belén, Martinez Antonio, Muñoz Montserrat, Prat Ale |
|
High levels of chromosomal copy number alterations and TP53 mutations correlate with poor outcome in younger breast cancer patients.
The American journal of pathology 2020 May . Koçak Ayla, Heselmeyer-Haddad Kerstin, Lischka Annette, Hirsch Daniela, Fiedler David, Hu Yue, Doberstein Natalie, Torres Irianna, Chen Wei-Dong, Gertz E Michael, Schäffer Alejandro A, Freitag-Wolf Sandra, Kirfel Jutta, Auer Gert, Habermann Jens K, Ried Thom |
|
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy.
Translational oncology 2020 May 13 (9): 100794. Omarini Claudia, Bettelli Stefania, Manfredini Samantha, Barbolini Monica, Isca Chrystel, Cortesi Giulia, Maiorana Antonino, Tazzioli Giovanni, Dominici Massimo, Piacentini Federi |
|
Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.
Breast cancer research and treatment 2020 May . Omilian Angela R, Wei Lei, Hong Chi-Chen, Bandera Elisa V, Liu Song, Khoury Thaer, Ambrosone Christine B, Yao So |
|
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Cancer medicine 2020 Apr . Welt Anja, Wiesweg Marcel, Theurer Sarah, Abenhardt Wolfgang, Groschek Matthias, Müller Lothar, Schröder Jan, Tewes Mitra, Chiabudini Marco, Potthoff Karin, Bankfalvi Agnes, Marschner Norbert, Schuler Martin, Breitenbücher Fra |
|
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
BMC cancer 2020 Apr 20 (1): 347. McCarthy Anne Marie, Kumar Nitya Pradeep, He Wei, Regan Susan, Welch Michaela, Moy Beverly, Iafrate A John, Chan Andrew T, Bardia Aditya, Armstrong Katri |
|
Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Mar . Beca Francisco, Krings Gregor, Chen Yunn-Yi, Hosfield Elizabeth M, Vohra Poonam, Sibley Richard K, Troxell Megan L, West Robert B, Allison Kimberly H, Bean Gregory |
|
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
Breast cancer research and treatment 2020 Feb . Shibayama Tomoko, Low Siew-Kee, Ono Makiko, Kobayashi Takayuki, Kobayashi Kokoro, Fukada Ippei, Ito Yoshinori, Ueno Takayuki, Ohno Shinji, Nakamura Yusuke, Takahashi Shun |
|
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Cancer research and treatment : official journal of Korean Cancer Association 2020 Feb . Guo Sanxing, Loibl Sibylle, Minckwitz Gunter von, Darb-Esfahani Silvia, Lederer Bianca, Denkert Carst |
|
Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity.
British journal of cancer 2020 Jan . Ahn Soomin, Kim Hyun Jeong, Kang Eunyoung, Kim Eun-Kyu, Kim Se Hyun, Kim Jee Hyun, Kim In Ah, Park So Ye |
|
Heterogeneity of genomic profile in patients with HER2-positive breast cancer.
Endocrine-related cancer 2020 Jan . Chen Bo, Zhang Guochun, Wei Guangnan, Wang Yulei, Guo Liping, Lin Jiali, Li Kai, Mok Hsiaopei, Cao Li, Ren Chongyang, Wen Lingzhu, Jia Minghan, Li Cheukfai, Hou Ting, Zhang Hanhan, Liu Jing, Balch Charles M, Liao Ni |
|
Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
BMC cancer 2020 Jan 20 (1): 72. Manoharan Vahinipriya, Karunanayake Eric Hamilton, Tennekoon Kamani Hemamala, De Silva Sumadee, Imthikab Ahamed Ilyas Ahamed, De Silva Kanishka, Angunawela Preethika, Vishwakula Sameera, Lunec Jo |
|
The association of modifiable breast cancer risk factors and somatic genomic alterations in breast tumors: The Cancer Genome Atlas Network.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2020 Jan . Heng Yujing J, Hankinson Susan E, Wang Jun, Alexandrov Ludmil B, Ambrosone Christine B, Andrade Victor Piana de, Brufsky Adam M, Couch Fergus J, King Tari A, Modugno Francesmary, Vachon Celine M, Eliassen A Heather, Tamimi Rulla M, Kraft Pet |
|
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Molecular genetics & genomic medicine 2019 Dec e1079. Chen Zhanhong, Sun Tian, Yang Ziyan, Zheng Yabing, Yu Ruoying, Wu Xue, Yan Junrong, Shao Yang W, Shao Xiying, Cao Wenming, Wang Xiaoj |
|
Genomic landscape of ductal carcinoma in situ and association with progression.
Breast cancer research and treatment 2019 Aug . Lin Chieh-Yu, Vennam Sujay, Purington Natasha, Lin Eric, Varma Sushama, Han Summer, Desa Manisha, Seto Tina, Wang Nicholas J, Stehr Henning, Troxell Megan L, Kurian Allison W, West Robert |
|
Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform.
Oncology reports 2019 Jul . Fan Chunni, Liu Ning, Fan Shulin, Yang Zhaoying, Ye Ning, Wang Ker |
|
Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab".
Annals of oncology : official journal of the European Society for Medical Oncology 2019 Jul 30 (7): 1180. Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga |
|
High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer.
Scientific reports 2019 Jul 9 (1): 10966. Lee Seung Eun, Lee Hye Seung, Kim Kyoung-Yeon, Park Jung-Hoon, Roh Hanseong, Park Ha Young, Kim Wan-Se |
|
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Breast cancer research and treatment 2019 Jul . Jacot William, Dalenc Florence, Lopez-Crapez Evelyne, Chaltiel Leonor, Durigova Anna, Gros Nathalie, Lozano Nicolas, Lacaze Jean-Louis, Pouderoux Stéphane, Gladieff Laurence, Romieu Gilles, Roché Henri, Filleron Thomas, Lamy Pierre-Je |
|
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Journal of cancer research and clinical oncology 2019 Jul . Elfgen C, Reeve K, Moskovszky L, Güth U, Bjelic-Radisic V, Fleisch M, Tausch C, Varga |
|
The molecular genetic make-up of male breast cancer.
Endocrine-related cancer 2019 Jul . Moelans Cathy B, de Ligt Joep, van der Groep Petra, Prins Pjotr, Besselink Nicolle, Hoogstraat Marlous, Ter Hoeve Natalie, Lacle Miangela, Kornegoor Robert, van der Pol Carmen, de Leng Wendy, Barbe Ellis, van der Vegt Bert, Martens John, Bult Peter, Smits Vincent Thbm, Koudijs Marco, Nijman Isaac, Voest Emile, Selenica Pier, Weigelt Britta, Reis-Filho Jorge, van der Wall Elsken, Cuppen Edwin, van Diest Paul |
|
Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis.
Clinical breast cancer 2019 May . Zhou Yunyun, Simmons Josh, Jordan Christina D, Sonbol Mohamad Bassam, Maihle Nita, Tang Shou-Chi |
|
Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Human pathology 2019 Apr 86 85-92. Zhai Jing, Giannini Gabriel, Ewalt Mark D, Zhang Elizabeth Y, Invernizzi Marta, Niland Joyce, Lai Lily |
|
Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Clinical breast cancer 2019 Apr 19 (2): 113-125.e4. Kotoula Vassiliki, Tsakiri Kalliopi, Koliou Georgia-Angeliki, Lazaridis Georgios, Papadopoulou Kyriaki, Giannoulatou Eleni, Tikas Ioannis, Christodoulou Christos, Chatzopoulos Kyriakos, Bobos Mattheos, Pentheroudakis George, Tsolaki Eleftheria, Batistatou Anna, Kotsakis Athanassios, Koutras Angelos, Linardou Helena, Razis Evangelia, Res Eleni, Pectasides Dimitrios, Fountzilas Geor |
|
Next generation sequencing of tissue and circulating tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy experience with breast malignancies.
Molecular cancer therapeutics 2019 Mar . Shatsky Rebecca, Parker Barbara A, Bui Nam Q, Helsten Teresa, Schwab Richard B, Boles Sarah G, Kurzrock Razel |
|
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
Journal of the National Cancer Institute 2019 Mar . Kim Rim S, Song Nan, Gavin Patrick G, Salgado Roberto, Bandos Hanna, Kos Zuzana, Floris Giuseppe, Eynden Gert Ggm Van den, Badve Sunil, Demaria Sandra, Rastogi Priya, Fehrenbacher Louis, Mamounas Eleftherios P, Swain Sandra M, Lawrence Wickerham D, Costantino Joseph P, Paik Soonmyung, Wolmark Norman, Geyer Charles E, Lucas Peter C, Pogue-Geile Katherine |
|
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Journal of cancer research and clinical oncology 2019 Feb . Chen Xinyi, Guo Yonghai, Ouyang Tao, Li Jinfeng, Wang Tianfeng, Fan Zhaoqing, Fan Tie, Lin Benyao, Xu Ye, Xie Yunt |
|
Genomic alterations associated with HER2+?breast cancer risk and clinical outcome in response to trastuzumab.
Molecular biology reports 2019 Feb 46 (1): 823-831. Singla Heena, Kaur Raman Preet, Shafi Gowhar, Vashistha Rajesh, Banipal Raja Paramjeet Singh, Kumar Vinod, Munshi Anja |
|
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Cancer cell 2019 Feb . Jiang Yi-Zhou, Ma Ding, Suo Chen, Shi Jinxiu, Xue Mengzhu, Hu Xin, Xiao Yi, Yu Ke-Da, Liu Yi-Rong, Yu Ying, Zheng Yuanting, Li Xiangnan, Zhang Chenhui, Hu Pengchen, Zhang Jing, Hua Qi, Zhang Jiyang, Hou Wanwan, Ren Luyao, Bao Ding, Li Bingying, Yang Jingcheng, Yao Ling, Zuo Wen-Jia, Zhao Shen, Gong Yue, Ren Yi-Xing, Zhao Ya-Xin, Yang Yun-Song, Niu Zhenmin, Cao Zhi-Gang, Stover Daniel G, Verschraegen Claire, Kaklamani Virginia, Daemen Anneleen, Benson John R, Takabe Kazuaki, Bai Fan, Li Da-Qiang, Wang Peng, Shi Leming, Huang Wei, Shao Zhi-Mi |
|
Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
Journal of the National Cancer Institute 2019 Feb . Nguyen Bastien, Veys Isabelle, Leduc Sophia, Bareche Yacine, Majjaj Samira, Brown David N, Boeckx Bram, Sotiriou Christos, Larsimont Denis, Desmedt Christi |
|
Molecular Alterations and Poziotinib Efficacy, a pan-HER inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancers: Combined Exploratory Biomarker Analysis from a Phase II Clinical Trial of Poziotinib for Refractory HER2-positive Breast Cancer Patients.
International journal of cancer 2019 Feb . Kim Ji-Yeon, Lee Eunjin, Park Kyunghee, Jung Hae Hyun, Park Woong-Yang, Lee Kyung-Hun, Sohn Joohyuk, Lee Keun Seok, Jung Kyung Hae, Kim Jee Hyun, Lee Ki Hyeong, Im Seock-Ah, Park Yeon H |
|
Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
International journal of molecular sciences 2019 Jan 20 (3): . Lopez Gianluca, Costanza Jole, Colleoni Matteo, Fontana Laura, Ferrero Stefano, Miozzo Monica, Fusco Nico |
|
Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.
PloS one 2019 14 (11): e0224726. Afkhami Michelle, Schmolze Daniel, Yost Susan E, Frankel Paul H, Dagis Andrew, Amanam Idoroenyi U, Telatar Milhan, Nguyen Kim, Yu Kim Wai, Luu Thehang, Pillai Raju, Aoun Patricia A, Mortimer Joanne, Yuan Yu |
|
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast cancer research : BCR 2019 03 21 (1): 39. Chia Stephen K L, Martin Miguel, Holmes Frankie A, Ejlertsen Bent, Delaloge Suzette, Moy Beverly, Iwata Hiroji, von Minckwitz Gunter, Mansi Janine, Barrios Carlos H, Gnant Michael, Tomaševic Zorica, Denduluri Neelima, Šeparovic Robert, Kim Sung-Bae, Jakobsen Erik Hugger, Harvey Vernon, Robert Nicholas, Smith John, Harker Graydon, Zhang Bo, Eli Lisa D, Ye Yining, Lalani Alshad S, Buyse Marc, Chan Arle |
|
Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.
Medicine 2018 Oct 97 (42): e12862. Lee Ju-Han, Jeong Hoiseon, Choi Jung-Woo, Oh Hwa Eun, Kim Young-S |
|
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Journal of hematology & oncology 2018 Oct 11 (1): 124. Liang Xu, Briaux Adrien, Becette Véronique, Benoist Camille, Boulai Anais, Chemlali Walid, Schnitzler Anne, Baulande Sylvain, Rivera Sofia, Mouret-Reynier Marie-Ange, Bouvet Laurence Venat, De La Motte Rouge Thibaut, Lemonnier Jérôme, Lerebours Florence, Callens Céli |
|
The prognostic effects of somatic mutations in ER-positive breast cancer.
Nature communications 2018 Sep 9 (1): 3476. Griffith Obi L, Spies Nicholas C, Anurag Meenakshi, Griffith Malachi, Luo Jingqin, Tu Dongsheng, Yeo Belinda, Kunisaki Jason, Miller Christopher A, Krysiak Kilannin, Hundal Jasreet, Ainscough Benjamin J, Skidmore Zachary L, Campbell Katie, Kumar Runjun, Fronick Catrina, Cook Lisa, Snider Jacqueline E, Davies Sherri, Kavuri Shyam M, Chang Eric C, Magrini Vincent, Larson David E, Fulton Robert S, Liu Shuzhen, Leung Samuel, Voduc David, Bose Ron, Dowsett Mitch, Wilson Richard K, Nielsen Torsten O, Mardis Elaine R, Ellis Matthew |
|
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Breast cancer research : BCR 2018 Aug 20 (1): 88. Liang Xu, Vacher Sophie, Boulai Anais, Bernard Virginie, Baulande Sylvain, Bohec Mylene, Bièche Ivan, Lerebours Florence, Callens Céli |
|
Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
Breast cancer research and treatment 2018 Jun . Yap Yoon-Sim, Munusamy Prabhakaran, Lim Cindy, Chan Claire H T, Prawira Aldo, Loke Sau-Yeen, Lim Swee-Ho, Ong Kong-Wee, Yong Wei-Sean, Ng Sarah B H, Tan Iain B H, Callen David F, Lim Jeffrey C T, Thike Aye-Aye, Tan Puay-Hoon, Lee Ann S |
|
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Breast cancer research and treatment 2018 Jun . Van Swearingen Amanda E D, Siegel Marni B, Deal Allison M, Sambade Maria J, Hoyle Alan, Hayes D Neil, Jo Heejoon, Little Paul, Dees Elizabeth Claire, Muss Hyman, Jolly Trevor, Zagar Timothy M, Patel Nirali, Miller C Ryan, Parker Joel S, Smith J Keith, Fisher Julie, Shah Nikita, Nabell Lisle, Nanda Rita, Dillon Patrick, Abramson Vandana, Carey Lisa A, Anders Carey |
|
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Oncotarget 2018 Jun 9 (44): 27380-27396. Cocciolone Valentina, Cannita Katia, Tessitore Alessandra, Mastroiaco Valentina, Rinaldi Lucia, Paradisi Stefania, Irelli Azzurra, Baldi Paola Lanfiuti, Sidoni Tina, Ricevuto Enrico, Dal Mas Antonella, Calvisi Giuseppe, Coletti Gino, Ciccozzi Antonietta, Pizzorno Laura, Resta Valter, Bafile Alberto, Alesse Edoardo, Ficorella Corra |
|
Phase II Study of Taselisib (GDC?0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 May . Dickler Maura N, Saura Cristina, Richards Donald, Krop Ian, Cervantes Andres, Bedard Phillipe L, Patel Manish R, Pusztai Lajos, Oliveira Mafalda, Cardenas Alison K, Cui Na, Wilson Timothy R, Stout Thomas J, Wei Michael C, Hsu Jerry Y, Baselga Jo |
|
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Breast (Edinburgh, Scotland) 2018 Apr 40 67-75. Takano Toshimi, Tsurutani Junji, Takahashi Masato, Yamanaka Takeharu, Sakai Kazuko, Ito Yoshinori, Fukuoka Junya, Kimura Hideharu, Kawabata Hidetaka, Tamura Kenji, Matsumoto Koji, Aogi Kenjiro, Sato Kazuhiko, Nishio Kazuto, Nakagawa Kazuhiko, Saeki Toshia |
|
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Nature communications 2018 Apr 9 (1): 1357. Chen Li, Yang Liu, Yao Ling, Kuang Xia-Ying, Zuo Wen-Jia, Li Shan, Qiao Feng, Liu Yi-Rong, Cao Zhi-Gang, Zhou Shu-Ling, Zhou Xiao-Yan, Yang Wen-Tao, Shi Jin-Xiu, Huang Wei, Hu Xin, Shao Zhi-Mi |
|
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Oncotarget 2018 Apr 9 (29): 20617-20630. De Mattos-Arruda Leticia, Ng Charlotte K Y, Piscuoglio Salvatore, Gonzalez-Cao Maria, Lim Raymond S, De Filippo Maria R, Fusco Nicola, Schultheis Anne M, Ortiz Carolina, Viteri Santiago, Arias Alexandra, Macedo Gabriel S, Oliveira Mafalda, Gomez Patricia, Teixidó Cristina, Nuciforo Paolo, Peg Vicente, Saura Cristina, Ramon Y Cajal Santiago, Casas Francesc Tresserra, Weigelt Britta, Cortes Javier, Seoane Joan, Reis-Filho Jorge |
|
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
Breast cancer (Tokyo, Japan) 2018 Apr . Sakai Hitomi, Tsurutani Junji, Iwasa Tsutomu, Komoike Yoshifumi, Sakai Kazuko, Nishio Kazuto, Nakagawa Kazuhi |
|
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology 2018 Apr . Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga |
|
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Apr 36 (10): 981-990. Zardavas Dimitrios, Te Marvelde Luc, Milne Roger L, Fumagalli Debora, Fountzilas George, Kotoula Vassiliki, Razis Evangelia, Papaxoinis George, Joensuu Heikki, Moynahan Mary Ellen, Hennessy Bryan T, Bieche Ivan, Saal Lao H, Stal Olle, Iacopetta Barry, Jensen Jeanette Dupont, O'Toole Sandra, Lopez-Knowles Elena, Barbaraeschi Mattia, Noguchi Shinzaburo, Azim Hatem A, Lerma Enrique, Bachelot Thomas, Wang Qing, Perez-Tenorio Gizeh, Can de Velde Cornelis J H, Rea Daniel W, Sabine Vicky, Bartlett John M S, Sotiriou Christos, Michiels Stefan, Loi Shere |
|
A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
Scientific reports 2018 Mar 8 (1): 4290. Alvarez-Garcia Virginia, Bartos Clare, Keraite Ieva, Trivedi Urmi, Brennan Paul M, Kersaudy-Kerhoas Maïwenn, Gharbi Karim, Oikonomidou Olga, Leslie Nicholas |
|
An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
British journal of cancer 2018 Mar . Gy?rffy Balázs, Pongor L?rinc, Bottai Giulia, Li Xiaotong, Budczies Jan, Szabó András, Hatzis Christos, Pusztai Lajos, Santarpia Libe |
|
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast cancer research and treatment 2018 Mar . Munzone Elisabetta, Gray Kathryn P, Fumagalli Caterina, Guerini-Rocco Elena, Láng István, Ruhstaller Thomas, Gianni Lorenzo, Kammler Roswitha, Viale Giuseppe, Di Leo Angelo, Coates Alan S, Gelber Richard D, Regan Meredith M, Goldhirsch Aron, Barberis Massimo, Colleoni Mar |
|
PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.
Thoracic cancer 2018 Mar . Fan Hongwei, Li Chao, Xiang Qian, Xu Ling, Zhang Zhuo, Liu Qianxin, Zhang Tonttong, Zhou Ying, Zhao Xia, Cui Yim |
|
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Cancer research and treatment : official journal of Korean Cancer Association 2018 Mar . Deng Ling, Zhu Xuehua, Sun Yun, Wang Jiemin, Zhong Xiaorong, Li Jiayuan, Hu Min, Zheng Ho |
|
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Histopathology 2018 Mar . Lozada John R, Basili Thais, Pareja Fresia, Alemar Barbara, Paula Arnaud C, Gularte-Merida Rodrigo, Giri Dilip D, Querzoli Patrizia, Cserni Gabor, Rakha Emad A, Foschini Maria Pia, Reis-Filho Jorge S, Brogi Edi, Weigelt Britta, Geyer Felipe |
|
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Molecular cancer 2018 Feb 17 (1): 67. Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Tomiguchi Mai, Sueta Aiko, Murakami Keiichi, Iwase Hirota |
|
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.
Nature communications 2018 10 9 (1): 4181. Pitt Jason J, Riester Markus, Zheng Yonglan, Yoshimatsu Toshio F, Sanni Ayodele, Oluwasola Olayiwola, Veloso Artur, Labrot Emma, Wang Shengfeng, Odetunde Abayomi, Ademola Adeyinka, Okedere Babajide, Mahan Scott, Leary Rebecca, Macomber Maura, Ajani Mustapha, Johnson Ryan S, Fitzgerald Dominic, Grundstad A Jason, Tuteja Jigyasa H, Khramtsova Galina, Zhang Jing, Sveen Elisabeth, Hwang Bryce, Clayton Wendy, Nkwodimmah Chibuzor, Famooto Bisola, Obasi Esther, Aderoju Victor, Oludara Mobolaji, Omodele Folusho, Akinyele Odunayo, Adeoye Adewunmi, Ogundiran Temidayo, Babalola Chinedum, MacIsaac Kenzie, Popoola Abiodun, Morrissey Michael P, Chen Lin S, Wang Jiebiao, Olopade Christopher O, Falusi Adeyinka G, Winckler Wendy, Haase Kerstin, Van Loo Peter, Obafunwa John, Papoutsakis Dimitris, Ojengbede Oladosu, Weber Barbara, Ibrahim Nasiru, White Kevin P, Huo Dezheng, Olopade Olufunmilayo I, Barretina Jor |
|
Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers.
NPJ breast cancer 2018 4 19. Yap Yoon-Sim, Singh Angad P, Lim John H C, Ahn Jin-Hee, Jung Kyung-Hae, Kim Jeongeun, Dent Rebecca A, Ng Raymond C H, Kim Sung-Bae, Chiang Derek |
|
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.
Journal of Cancer 2018 9 (7): 1145-1151. Park In Hae, Kong Sun-Young, Kwon Youngmee, Kim Min Kyeong, Sim Sung Hoon, Joo Jungnam, Lee Keun Se |
|
Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.
American journal of cancer research 2018 8 (9): 1873-1886. Li Huiping, Xu Yaping, Zhao Fangyuan, Song Guohong, Rugo Hope S, Zhang Yan, Yang Ling, Liu Xiaoran, Shao Bin, Yang Liang, Liu Yaxin, Ran Ran, Zhang Ruyan, Guan Yanfang, Chang Lianpeng, Yi X |
|
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
PloS one 2018 13 (9): e0203495. Li Guoli, Guo Xinwu, Chen Ming, Tang Lili, Jiang Hui, Day Julia X, Xie Yueliang, Peng Limin, Xu Xunxun, Li Jinliang, Wang Shouman, Xiao Zhi, Dai Lizhong, Wang J |
|
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.
JCO precision oncology 2018 2018 . Meric-Bernstam Funda, Zheng Xiaofeng, Shariati Maryam, Damodaran Senthil, Wathoo Chetna, Brusco Lauren, Demirhan Mehmet Esat, Tapia Coya, Eterovic Agda Karina, Basho Reva K, Ueno Naoto T, Janku Filip, Sahin Aysegul, Rodon Jordi, Broaddus Russell, Kim Tae-Beom, Mendelsohn John, Mills Shaw Kenna R, Tripathy Debu, Mills Gordon B, Chen K |
|
Genetic alterations in sporadic triple negative breast cancer.
Breast (Edinburgh, Scotland) 2017 Dec 38 30-38. Pop Laura-Ancuta, Cojocneanu-Petric Roxana-Maria, Pileczki Valentina, Morar-Bolba Gabriela, Irimie Alexandru, Lazar Vladimir, Lombardo Claudio, Paradiso Angelo, Berindan-Neagoe Ioa |
|
Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer.
BBA clinical 2017 Dec 8 56-65. Ojo Diane, Seliman Maryam, Tang Da |
|
Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Nov . Rossi Giovanna, Mu Zhaomei, Rademaker Alfred, Austin Laura, Strickland Kimberly S, Lima Barros Costa Ricardo, Nagy Rebecca, Zagonel Vittorina, Taxter Timothy J, Behdad Amir, Wehbe Firas H, Platanias Leonidas C, Gradishar William, Cristofanilli Massi |
|
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast cancer research and treatment 2017 Nov . Rimawi Mothaffar F, De Angelis Carmine, Contreras Alejandro, Pareja Fresia, Geyer Felipe C, Burke Kathleen A, Herrera Sabrina, Wang Tao, Mayer Ingrid A, Forero Andres, Nanda Rita, Goetz Matthew P, Chang Jenny C, Krop Ian E, Wolff Antonio C, Pavlick Anne C, Fuqua Suzanne A W, Gutierrez Carolina, Hilsenbeck Susan G, Li Marilyn M, Weigelt Britta, Reis-Filho Jorge S, Kent Osborne C, Schiff Rach |
|
Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN.
Oncotarget 2017 Oct 8 (48): 84426-84433. Laes Jean-François, Sauvage Sebastien, Ghitti Grego |
|
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Sep . Lavigne Marion, Menet Emmanuelle, Tille Jean-Christophe, Lae Marick, Fuhrmann Laetitia, Bonneau Claire, Deniziaut Gabrielle, Melaabi Samia, Ng Charlotte C K, Marchiò Caterina, Rouzier Roman, Bièche Ivan, Vincent-Salomon An |
|
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
Annals of oncology : official journal of the European Society for Medical Oncology 2017 Sep . Bernichon E, Vallard A, Wang Q, Attignon V, Pissaloux D, Bachelot T, Heudel P E, Ray-Coquard I, Bonnet E, de la Fouchardière A, Faure C, Chopin N, Beurrier F, Racadot S, Sunyach M P, Rancoule C, Perol D, Corset V, Agrapart V, Tinquaut F, Blay J Y, Magné N, Trédan |
|
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aug JCO2017733246. Goetz Matthew P, Suman Vera J, Reid Joel M, Northfelt Don W, Mahr Michael A, Ralya Andrew T, Kuffel Mary, Buhrow Sarah A, Safgren Stephanie L, McGovern Renee M, Black John, Dockter Travis, Haddad Tufia, Erlichman Charles, Adjei Alex A, Visscher Dan, Chalmers Zachary R, Frampton Garrett, Kipp Benjamin R, Liu Minetta C, Hawse John R, Doroshow James H, Collins Jerry M, Streicher Howard, Ames Matthew M, Ingle James |
|
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.
Oncotarget 2017 Jun . Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Tomiguchi Mai, Sueta Aiko, Murakami Keiichi, Omoto Yoko, Iwase Hirota |
|
Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Bulletin of experimental biology and medicine 2017 Jun 163 (2): 250-254. Filipenko M L, Os'kina N A, Oskorbin I A, Mishukova O V, Ovchinnikova L K, Gershtein E S, Kushlinskii N |
|
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Oncology 2017 May 93 (1): . Nishimura Reiki, Toh Uhi, Tanaka Maki, Saimura Michiyo, Okumura Yasuhiro, Saito Tsuyoshi, Tanaka Toshihiro, Teraoka Megumi, Shimada Kazuo, Katayama Kazuhisa, Koga Toshihiro, Kurashita Kaname, Hasegawa Satoshi, Todoroki Hidekazu, Kai Yuichiro, Ohi Yasuyo, Toyoshima Satoshi, Arima Nobuyuki, Mitsuyama Shoshu, Tamura Kaz |
|
Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Apr . Pierobon Mariaelena, Ramos Corrine, Wong Shukmei, Hodge K Alex, Aldrich Jessica, Byron Sara A, Anthony Stephen P, Robert Nicholas J, Northfelt Donald W, Jahanzeb Mohammad, Vocila Linda, Wulfkuhle Julia D, Gambara Guido, Gallagher Rosa Isela, Dunetz Bryant, Hoke Nicholas, Dong Ting, Craig David W, Cristofanilli Massimo, Leyland Jones Brian, Liotta Lance, O'Shaughnessy Joyce A, Carpten John D, Petricoin Emanuel |
|
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Mar . Pang Jia-Min B, Savas Peter, Fellowes Andrew P, Mir Arnau Gisela, Kader Tanjina, Vedururu Ravikiran, Hewitt Chelsee, Takano Elena A, Byrne David J, Choong David Yh, Millar Ewan Ka, Lee C Soon, O'Toole Sandra A, Lakhani Sunil R, Cummings Margaret C, Mann G Bruce, Campbell Ian G, Dobrovic Alexander, Loi Sherene, Gorringe Kylie L, Fox Stephen |
|
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Oncotarget 2017 Mar . Kim Ji-Yeon, Lee Eunjin, Park Kyunghee, Park Woong-Yang, Jung Hae Hyun, Ahn Jin Seok, Im Young-Hyuck, Park Yeon H |
|
Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Cancer discovery 2017 Mar . Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra, Savage Heidi, Sampath Deepak, Salphati Laurent, Lin Ray, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D, Baselga Jo |
|
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Oncotarget 2017 Mar 8 (12): 20252-20265. Li Xiang, Zhang Ruishan, Liu Zhuangkai, Li Shuang, Xu Ho |
|
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2.
British journal of cancer 2017 Feb . Moynahan Mary Ellen, Chen David, He Wei, Sung Patricia, Samoila Aliaksandra, You Daoqi, Bhatt Trusha, Patel Parul, Ringeisen Francois, Hortobagyi Gabriel N, Baselga Jose, Chandarlapaty Sar |
|
Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.
Breast cancer research and treatment 2017 Feb 161 (3): 491-499. Ademuyiwa Foluso O, Tao Yu, Luo Jingqin, Weilbaecher Katherine, Ma Cynthia |
|
Identification of frequent somatic mutations in inflammatory breast cancer.
Breast cancer research and treatment 2017 Feb . Matsuda Naoko, Lim Bora, Wang Ying, Krishnamurthy Savitri, Woodward Wendy, Alvarez Ricardo H, Lucci Anthony, Valero Vicente, Reuben James M, Meric-Bernstam Funda, Ueno Naoto |
|
The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
Cancer investigation 2017 Jan 35 (1): 36-42. Azizi Tabesh Ghasem, Izadi Pantea, Fereidooni Forouzandeh, Emami Razavi Amir Nader, Tavakkoly Bazzaz Jav |
|
Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
NPJ breast cancer 2017 3 24. Chen Yu-Hsiang, Hancock Bradley A, Solzak Jeffrey P, Brinza Dumitru, Scafe Charles, Miller Kathy D, Radovich Mil |
|
The fate of BRCA1-related germline mutations in triple-negative breast tumors.
American journal of cancer research 2017 7 (1): 98-114. Kotoula Vassiliki, Fostira Florentia, Papadopoulou Kyriaki, Apostolou Paraskevi, Tsolaki Eleftheria, Lazaridis Georgios, Manoussou Kyriaki, Zagouri Flora, Pectasides Dimitrios, Vlachos Ioannis, Tikas Ioannis, Lakis Sotiris, Konstantopoulou Irene, Pentheroudakis George, Gogas Helen, Papakostas Pavlos, Christodoulou Christos, Bafaloukos Dimitrios, Razis Evangelia, Karavasilis Vasilios, Bamias Christina, Yannoukakos Drakoulis, Fountzilas Geor |
|
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
PLoS medicine 2016 Dec 13 (12): e1002201. Lefebvre Celine, Bachelot Thomas, Filleron Thomas, Pedrero Marion, Campone Mario, Soria Jean-Charles, Massard Christophe, Lévy Christelle, Arnedos Monica, Lacroix-Triki Magali, Garrabey Julie, Boursin Yannick, Deloger Marc, Fu Yu, Commo Frédéric, Scott Véronique, Lacroix Ludovic, Dieci Maria Vittoria, Kamal Maud, Diéras Véronique, Gonçalves Anthony, Ferrerro Jean-Marc, Romieu Gilles, Vanlemmens Laurence, Mouret Reynier Marie-Ange, Théry Jean-Christophe, Le Du Fanny, Guiu Séverine, Dalenc Florence, Clapisson Gilles, Bonnefoi Hervé, Jimenez Marta, Le Tourneau Christophe, André Fabri |
|
SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers.
European journal of human genetics : EJHG 2016 Dec . Puzone Roberto, Pfeffer Ulri |
|
Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Feb 30 (5_suppl): 277. Balar Arjun Vasant, Iyer Gopa, Al-Ahmadie Hikmat, Janakiraman Manickam, Ostrovnaya Irina, Regazzi Ashley Marie, Garcia-Grossman Ilana Rebecca, Pendse Deepa, Bochner Bernard, Bajorin Dean F, Milowsky Matthew I, Solit David |
|
A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e11070. Jinno H, Sato T, Takahashi M, Hayashida T, Sakata M, Hirose S, Kitagawa |
|
Association of PIK3CA kinase domain mutations with poor prognosis in operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e21060. Voutsina A, Kalikaki A, Mitsi V, Stathopoulos E, Georgoulias V, Mavroudis |
|
Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphathidylinositol-3-kinase (PI3K) pathway status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e21130. De Mattos-Arruda L, Oliveira M, Sánchez-Ollé G, Moreno-Fernandez D, Graña B, Cortes J, Bellet M, Di Cosimo S, Gomez Pardo P, Rodon Ahnert J, Perez-Garcia J M, Vidal M, Muñoz-Couselo E, Hernandez-Losa J, Vivancos A, Prudkin L, Aura C, Baselga J, Tabernero J, Saura |
|
Heterogeneous prevalence of mutations in KRAS, BRAF, and PIK3CA genes among Sardinian patients with colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e14100. Palomba G, Colombino M, Contu A S, Massidda B, Baldino G, Ionta M T, Pazzola A, Capelli F, Trova V, Sedda T, Farris A, Tanda F, Budroni M, Palmieri G, Cossu A, |
|
Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): 533. Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart M J, Phillips W A, McArthur G A, Sotiriou |
|
Use of multiplex mutation genotyping to identify novel and protective mutations in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 (15_suppl): 11004. Kalinsky K, Jacks L M, Hedvat C, Bhanot U, Patil S, Heguy A, Asher M, Drobnjak M, Hudis C, Moynahan M |
|
Clinical-Pathologic Analysis of Breast Cancer With PIK3CA Mutations in Chinese Women.
Technology in cancer research & treatment 0 19 1533033820950832. Lian Jing, Xu En-Wei, Xi Yan-Feng, Wang Hui-Wen, Bu Peng, Wang Jin-Fen, Wang Li-X |
- Page last reviewed:Oct 1, 2020
- Page last updated:Oct 23, 2020
- Content source: